Astel­las takes $435M+ write­down on Evren­zo, hear­ing loss can­di­date and T cell ther­a­py deal

Astel­las is book­ing hun­dreds of mil­lions of dol­lars in im­pair­ment loss­es this year af­ter end­ing a TCR T cell ther­a­py de­vel­op­ment deal, drop­ping a part­nered can­di­date for hear­ing loss and see­ing dis­ap­point­ing sales for its drug Evren­zo in Japan and Eu­rope.

Astel­las $ALP­MY dipped a lit­tle over 2% Tues­day, clos­ing at $14.40.

As Adap­ti­m­mune dis­closed in March, Astel­las and Adap­ti­m­mune have end­ed a 2020 agree­ment to de­vel­op cell ther­a­pies — and Astel­las is tak­ing an im­pair­ment loss of in­tan­gi­ble as­sets of ¥4.7 bil­lion ($35.1 mil­lion) thanks to the ter­mi­na­tion, Astel­las an­nounced Tues­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER